Showing 18 of 58 recruiting trials for “nodal-marginal-zone-b-cell-lymphoma”
Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
👨⚕️ Catherine S Diefenbach, Laura and Isaac Perlmutter Cancer Center at NYU Langone📍 9 sites📅 Started Nov 2022View details ↗
Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
👨⚕️ Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC📍 31 sites📅 Started Aug 2022View details ↗
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
👨⚕️ Wenbin Qian, 2nd Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Jul 2022View details ↗
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
👨⚕️ Stefano Luminari, MD, Ematologia, AUSL IRCCS Reggio Emilia📍 2 sites📅 Started Feb 2022View details ↗
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
👨⚕️ Christopher J Melani, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Feb 2018View details ↗
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
👨⚕️ Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center📍 10 sites📅 Started Nov 2016View details ↗
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
← PreviousPage 3 of 3
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →